2024-02-13 00:50:00 ET
Summary
- Let's take a look at the landscape for GLP-1 drug development (including the drugs that target associated hormones).
- Novo Nordisk has had a spectacular success with semaglutide (Ozempic/Wegovy), and its effects on weight loss have been established to an undeniable degree.
- If you go back a year or two, you had Eli Lilly working on an obesity approval for trizepatide (Mounjaro/Zepbound), which was already being vigorously prescribed off-label.
Let's take a look at the landscape for GLP-1 drug development (including the drugs that target associated hormones), because this hot area illustrates the fortunes of the drug business pretty vividly....
Read the full article on Seeking Alpha
For further details see:
The GLP-1 Demolition Derby